Prostate cancer: local control and radiotherapy matter in prostate cancer
- PMID: 19424171
- DOI: 10.1038/nrurol.2009.56
Prostate cancer: local control and radiotherapy matter in prostate cancer
Abstract
In a study published in The Lancet, long-term androgen suppression (AS) combined with radiotherapy, compared with AS alone, improved outcomes in patients with locally advanced but nonmetastatic prostate cancer. The combined therapy significantly reduced prostate-cancer-specific deaths at 10 years from 23.9% to 11.9% (P <0.001), and improved overall survival.
Comment on
-
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Lancet. 2009. PMID: 19091394 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials